Effects of HIV infection on metastatic cervical cancer and age at diagnosis among patients in Lusaka, Zambia.
HIV
Zambia
age
cervical cancer
stage
Journal
International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics
ISSN: 1879-3479
Titre abrégé: Int J Gynaecol Obstet
Pays: United States
ID NLM: 0210174
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
revised:
12
05
2021
received:
18
02
2021
accepted:
11
06
2021
pubmed:
15
6
2021
medline:
9
2
2022
entrez:
14
6
2021
Statut:
ppublish
Résumé
To examine the association between the duration of HIV infection and the stage of cervical cancer in Lusaka, Zambia. This retrospective case-case study included 1583 cervical cancer patients from the Cancer Diseases Hospital in Lusaka, Zambia. A sub-population of HIV-positive patients with additional clinical HIV information was identified following linkage of cancer and HIV databases. Logistic regression models examined the relationship between HIV status and early-onset cervical cancer diagnosis, and between HIV infection duration and initial diagnosis of metastatic cervical cancer. The study population had an average age of 49 years and 40.9% had an initial diagnosis of metastatic cancer. HIV-positive women were more than twice as likely to be diagnosed at early-onset cervical cancer compared with HIV-negative women. Among the sub-population of HIV-positive patients, a longer duration of HIV infection was associated with 20% lowered odds of initial metastatic cancer diagnosis. The availability, accessibility, and impact of the cervical screening program in this population should be further examined to elucidate the relationship between cervical screening, age, and duration of HIV infection and the the stage of diagnosis of cervical cancer.
Identifiants
pubmed: 34121186
doi: 10.1002/ijgo.13784
pmc: PMC8669036
mid: NIHMS1714782
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
521-528Subventions
Organisme : NCI NIH HHS
ID : R25 CA112383
Pays : United States
Informations de copyright
© 2021 International Federation of Gynecology and Obstetrics.
Références
Sex Transm Dis. 2017 Nov;44(11):653-655
pubmed: 28876316
Health Policy Plan. 2009 Jul;24(4):239-52
pubmed: 19491291
Cancer. 2015 Jun 15;121(12):2063-71
pubmed: 25739496
J Clin Oncol. 2015 Jul 20;33(21):2376-83
pubmed: 26077242
MMWR Recomm Rep. 1992 Dec 18;41(RR-17):1-19
pubmed: 1361652
Int J Gynecol Cancer. 2020 May;30(5):613-618
pubmed: 32200353
BMC Infect Dis. 2007 Jul 16;7:77
pubmed: 17634108
PLoS One. 2015 Apr 17;10(4):e0122169
pubmed: 25885821
Lancet HIV. 2017 Nov;4(11):e495-e504
pubmed: 28803888
BMC Cancer. 2015 Jul 24;15:541
pubmed: 26205980
N Engl J Med. 1997 Nov 6;337(19):1343-9
pubmed: 9358128
J Clin Oncol. 2014 Aug 1;32(22):2344-50
pubmed: 24982448
Rev Obstet Gynecol. 2009 Fall;2(4):240-4
pubmed: 20111660
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Int J Gynecol Cancer. 2015 Jan;25(1):98-105
pubmed: 25423318
Health Aff (Millwood). 2012 Jul;31(7):1406-14
pubmed: 22778329
Gynecol Oncol Rep. 2017 Jul 21;21:101-108
pubmed: 28819634
J Glob Oncol. 2018 Sep;4:1-9
pubmed: 30241147
Obstet Gynecol. 2012 Nov;120(5):1117-23
pubmed: 23090530
Health Policy Plan. 2016 Sep;31(7):897-909
pubmed: 27017824
Obstet Gynecol. 2000 Sep;96(3):403-9
pubmed: 10960634
Eur J Cancer Prev. 2008 Nov;17(6):545-54
pubmed: 18941376
PLoS Med. 2011 May;8(5):e1001032
pubmed: 21610859
Br Med J (Clin Res Ed). 1988 Feb 6;296(6619):386-91
pubmed: 3125911
Health Aff (Millwood). 2012 Jul;31(7):1478-88
pubmed: 22778337